Back grey_arrow_rt.gif
 
 
Intelence (etravirine) label revised to includenew drug-drug interaction information
 
 
  FDA recently updated Intelence (etravirine) label to include drug-drug interaction information between etravirine and fluconazole, voriconazole, lopinavir/ritonavir tablets and clopidogrel. The major changes to Section 7 Drug Interactions are summarized below.
 
In additon the magnitude of the interaction for etravirine in the presence of fluconazole, voriconazole and lopinavir/ritonavir tablets can be found in section 12.3 Pharmacokinetics.
 
Please also refer to
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s003lbl.pdf to view the complete updated label. Etravirine - fluconazole and voriconazole:
 
Co-administration of etravirine and fluconazole or voriconazole significantly increased etravirine exposures.
 
The amount of safety data at these increased etravirine exposures is limited; therefore, etravirine and fluconazole or voriconazole should be co-adminstered with caution. No dose adjustments of Intelence, fluconazole or voriconazole is needed.
 
Etravirine - lopinavir/ritonavir tablets: Intelence and Kaletra (lopinavir/ritonavir) tablets can be coadministered without dose adjustment
 
Etravirine - clopidogrel: Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Intelence. Alternative to clopidogrel should be considered.
 
Etravirine is a Nonnucleoside R everse Transcriptase Inhibitors (NNRTI) made by Tibotec Therapeutics .
 
Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org